A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Multiple Intravenous Doses of ANZ-521 in Hepatitis C Patients.
Phase of Trial: Phase I/II
Latest Information Update: 09 Dec 2009
At a glance
- Drugs ANZ 521 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 23 Feb 2009 Planned end date changed from 1 May 2010 to 1 Feb 2009.
- 19 Feb 2009 Planned number of patients changed from 25 to 5 as reported by ClinicalTrials.gov.
- 19 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.